Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

KLRS Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Kalaris Therapeutics IncNASDAQ: KLRS

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $74K fell 99.9% year over year. Sequentially, it fell 99.9% from the prior quarter. Over 3 fiscal years it compounded at +132.0% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$74K-99.9% QoQ
Last fiscal yearDec 2025
$159.61M+759961.9% YoY
LTMMar 2026
$52.42M— YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.9%——
1 year+759961.9%——
3-year CAGR+132.0%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
159.61M USD
Year-over-year change
+759961.9%
4-year CAGR
+412.1%

Financing Cash Flow vs competitors

How KLRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of +132.0% compares with a peer median of +276.5%.
KLRS Competitors
Financing Cash Flow for KLRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026$164.18M USD+40238.1%+646.7%2305.2%
IMAImageneBio IncLTM Mar 2026$132.22M USD—+398.3%—
STROSutro Biopharma, Inc.LTM Mar 2026$103.05M USD+5.6%-90.3%103.5%
STTKShattuck Labs, Inc.LTM Mar 2026$70.43M USD+7606.1%+538.8%7043.4%
KLRSKalaris Therapeutics IncLTM Mar 2026$52.42M USD—+132.0%—
IFRXInflaRx N.V.LTM Mar 2026€6.23M EUR-77.3%+154.7%21245.3%
CNTBConnect Biopharma Holdings LimitedFY2025$1.09M USD+381.5%—1707.8%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$342K USD-100.2%——
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD-100.0%-46.9%—
Peer median (excluding KLRS) —+5.6%+276.5%2305.2%

Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(171.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Depreciation & Amortization1.12M00013K
Deferred Income Tax00000
Stock-Based Compensation0271K148K00
Change in Working Capital19.35M3.4M(1.09M)(25.31M)3.43M
Accounts Receivables400K00206K0
Inventory00000
Accounts Payables20.29M1.83M(402K)(28.86M)(88K)
Other Working Capital(1.34M)1.57M(690K)3.35M3.52M
Other Non-Cash Items45.17M2.04M1.51M16.37M(2.98M)
Operating Cash Flow(106.32M)(9.78M)(14.13M)(67.71M)(42.98M)
Capital Expenditures(26K)000(200K)
Acquisitions (Net)00000
Purchases of Investments(76.59M)000(34.52M)
Sales of Investments262.6M0095M15M
Other Investing Activities00000
Investing Cash Flow185.98M0095M(19.72M)
Debt Repayment04.3M6M07.5M
Common Stock Issued232K0021K50M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities05K1.5M0102.11M
Financing Cash Flow232K12.78M14.24M21K159.61M
Effect of Forex Changes(896K)00852K(117.15M)
Net Change in Cash79M3M110K28.17M(20.24M)
Free Cash Flow(106.35M)(9.78M)(14.13M)(67.71M)(43.18M)

Kalaris Therapeutics Inc

NASDAQ:KLRS

Intrinsic Alpha fair value

Locked

Current Price

$2.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.